Partner Headlines - EXEL

  1. Exelixis Prices 25M Share Offering @$5.40/Share

    Benzinga
  2. Benzinga's Top #PreMarket Losers

    Benzinga
  3. Ethical-Drug Firms Horizon Pharma, Bristol-Myers Rally

    IBD
  4. Bristol-Myers: kidney drug win

    IBD
  5. Market Update: Monday's Mid-Day Movers; Greece Opens Banks; Gold ...

    Benzinga
  6. Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer

    IBD
  7. Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley ...

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. Exelixis Announces Start of Phase 1 Trial of Cabozantinib in ...

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. Watch These 10 Stocks Over The Weekend

    Benzinga
  12. Morning Market Gainers

    Benzinga
  13. Benzinga's Top #PreMarket Gainers

    Benzinga
  14. Morning Market Gainers

    Benzinga
  15. Benzinga's Top #PreMarket Gainers

    Benzinga
  16. Exelixis Data Release Upcoming; Options Activity Spiking

    Benzinga
  17. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  18. 5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic ...

    GuruFocus
  19. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion ...

    Benzinga
  20. Mid-Morning Market Update: Markets Open Lower; Weatherford To ...

    Benzinga
  21. Morning Market Losers

    Benzinga
  22. Events for the Week of Nov. 17-21, 2014

    Benzinga
  23. Morning Market Movers

    Benzinga
  24. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  25. Stocks Hitting 52-Week Lows

    Benzinga
  26. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  27. Midday Losers From Tuesday, September 2

    Benzinga
  28. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  29. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  30. Stocks Hitting 52-Week Lows

    Benzinga
  31. Morning Market Losers

    Benzinga
  32. Benzinga's Top Downgrades

    Benzinga
  33. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  34. Stocks To Watch For September 2, 2014

    Benzinga
  35. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  36. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  37. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  38. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  39. Morning Market Movers

    Benzinga
  40. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  41. Benzinga's Top #PreMarket Gainers

    Benzinga
  42. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  43. Benzinga's Top #PreMarket Gainers

    Benzinga
  44. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  45. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  46. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  47. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  48. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  49. Stocks Hitting 52-Week Lows

    Benzinga
  50. Morning Market Losers

    Benzinga
  51. Benzinga's Top #PreMarket Losers

    Benzinga
  52. Morning Market Movers

    Benzinga
  53. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  54. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  55. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  56. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  57. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  58. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  59. US Stock Futures Up After Upbeat China Data

    Benzinga
  60. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  61. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  62. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  63. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  64. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  65. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  66. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  67. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  68. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  69. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  70. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  71. Health Care Sector Wrap

    FoxBusiness
  72. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  73. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  74. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  75. Exelixis Proposed Offering 20M Shares

    Benzinga
  76. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  77. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  78. Benzinga's Top Pre-Market Gainers

    Benzinga
  79. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  80. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  81. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  82. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  83. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  84. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  85. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  86. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  87. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  88. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  89. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  90. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  91. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  92. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  93. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  94. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  95. Notable Call Options Activity on Exelixis

    Benzinga
  96. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  97. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!